ProQR Therapeutics N.V.

DB:0PQ Stock Report

Market Cap: €182.0m

ProQR Therapeutics Management

Management criteria checks 3/4

ProQR Therapeutics' CEO is Daniel de Boer, appointed in Feb 2012, has a tenure of 13.08 years. total yearly compensation is €2.44M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.68% of the company’s shares, worth €1.24M. The average tenure of the management team and the board of directors is 5.2 years and 6.9 years respectively.

Key information

Daniel de Boer

Chief executive officer

€2.4m

Total compensation

CEO salary percentage21.5%
CEO tenure13.1yrs
CEO ownership0.7%
Management average tenure5.2yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Daniel de Boer's remuneration changed compared to ProQR Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-€24m

Jun 30 2024n/an/a

-€22m

Mar 31 2024n/an/a

-€27m

Dec 31 2023€2m€524k

-€28m

Sep 30 2023n/an/a

-€36m

Jun 30 2023n/an/a

-€54m

Mar 31 2023n/an/a

-€59m

Dec 31 2022€2m€504k

-€64m

Sep 30 2022n/an/a

-€69m

Jun 30 2022n/an/a

-€61m

Mar 31 2022n/an/a

-€63m

Dec 31 2021€2m€449k

-€61m

Sep 30 2021n/an/a

-€57m

Jun 30 2021n/an/a

-€55m

Mar 31 2021n/an/a

-€43m

Dec 31 2020€3m€449k

-€47m

Sep 30 2020n/an/a

-€52m

Jun 30 2020n/an/a

-€51m

Mar 31 2020n/an/a

-€58m

Dec 31 2019€2m€449k

-€56m

Sep 30 2019n/an/a

-€51m

Jun 30 2019n/an/a

-€45m

Mar 31 2019n/an/a

-€40m

Dec 31 2018€1m€445k

-€37m

Compensation vs Market: Daniel's total compensation ($USD2.64M) is above average for companies of similar size in the German market ($USD801.61K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.

CEO

Daniel de Boer (41 yo)

13.1yrs

Tenure

€2,439,000

Compensation

Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel de Boer
Founder13.1yrs€2.44m0.68%
€ 1.2m
Domenico Valerio
Founder & Independent Member of Supervisory Boardno data€150.00k0.41%
€ 742.1k
Rene Beukema
Chief Corporate Development Officer2.8yrs€1.31m0.45%
€ 811.4k
Gerard Platenburg
Co-Founder13.1yrs€34.00kno data
Jurriaan Dekkers
Chief Financial Officer2.3yrsno datano data
Sheila Sponselee
Chief People & Operations Officer5.2yrsno datano data
Sarah Kiely
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Sandra van der Kolk
Junior Financial Controllerno datano datano data

5.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 0PQ's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Domenico Valerio
Founder & Independent Member of Supervisory Board11.2yrs€150.00k0.41%
€ 742.1k
Alison Lawton
Independent Member of Supervisory Board10.5yrs€126.00k0%
€ 0
Phillip Zamore
Member of Scientific Advisory Board7.8yrsno datano data
Theresa Heggie
Supervisory Board Member1.8yrs€271.00k0.026%
€ 46.7k
James Shannon
Independent Chairman of Supervisory Board & Chairman of Scientific Advisory Board8.8yrs€132.00k0.060%
€ 108.6k
Bart Filius
Independent Supervisory Board Member5.8yrs€127.00k0%
€ 0
Martin Maier
Supervisory Board Member & Member of Scientific Advisory Board4.7yrsno datano data
Peter Beal
Chief ADAR Scientist & Member of Scientific Advisory Board6.9yrsno datano data
Yi-Tao Yu
Member of Scientific Advisory Board6.8yrsno datano data
Begona Carreno
Member of the Board of Directors2.2yrs€84.00k0%
€ 0

6.9yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 0PQ's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/10 07:24
End of Day Share Price 2025/03/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ProQR Therapeutics N.V. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Eliana MerleCantor Fitzgerald & Co.
Steven SeedhouseCGS International